Medtronic plc

Medtronic derives the majority of its revenue from disposables, consumables, and procedure-linked products such as leads, catheters, and sensors, creating a structurally repeat-purchase dynamic across the Cardiovascular and Neuroscience portfolios. FY2025 enterprise revenue of $33.5 billion reflected growth across all three remaining segments, though visibility lacks the contractual duration of subscription software.

After the announced Diabetes divestiture, Medtronic operates through three primary segments: Cardiovascular ($12.5 billion in FY2025, approximately 37% of total), Neuroscience ($9.8 billion, approximately 29%), and Medical Surgical. While no single division holds a majority of revenue, Cardiovascular concentration and the correlated exposure of all segments to hospital capital budgets limit diversification credit.

International markets account for roughly 50% of Medtronic's revenue, distributed across the EU, Japan, and emerging markets, with the US comprising the other half. The near-equal split provides meaningful geographic balance, but the US still represents approximately 50% of revenue, exceeding the 40% threshold for the highest diversification marks.

Medical device manufacturing and R&D require proportional investment as Medtronic scales into new therapy areas. Adjusted gross margin held near 65% in FY2026 quarterly results, consistent with prior years but not materially expanding, reflecting the capex and labor intensity of multi-segment device production consistent with sector norms.

A large share of Medtronic's revenue derives from implanted device therapies and their associated ongoing consumable supply, making demand mission-critical for patients receiving pacemakers, neurostimulators, or spinal implants. Hospital enterprise agreements and GPO contracts provide contractual coverage for a meaningful share of purchasing, placing quality clearly above purely transactional categories.